Skip to main content

Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.

Publication ,  Journal Article
Sardella, G; Beerkens, FJ; Dangas, G; Cao, D; Baber, U; Sartori, S; Cohen, DJ; Briguori, C; Gil, R; Nicolas, J; Zhang, Z; Dudek, D; Weisz, G ...
Published in: EuroIntervention
December 2, 2022

BACKGROUND: Prior coronary artery bypass graft surgery (CABG) patients undergoing percutaneous coronary intervention (PCI) are often older and present with multiple comorbidities. Ticagrelor monotherapy after a short course of dual antiplatelet therapy (DAPT) has emerged as an effective bleeding-avoidance strategy among high-risk patients. AIMS: We aimed to examine the effects of ticagrelor with or without aspirin in prior CABG patients undergoing PCI within the TWILIGHT trial. METHODS: After 3 months of ticagrelor plus aspirin, patients were randomised to either aspirin or placebo, in addition to ticagrelor, for 12 months and compared by prior CABG status. The primary endpoint was Bleeding Academic Research Consortium (BARC) type 2, 3 or 5 bleeding. The key secondary endpoint was all-cause death, myocardial infarction (MI), or stroke. RESULTS: Out of 7,119 patients, a total of 703 (10.8%) patients had prior CABG within the randomised cohort. Prior CABG patients had more comorbidities and a higher incidence of BARC type 2, 3, or 5 bleeding and death, MI or stroke at 1 year after randomisation, compared with patients without prior CABG. Ticagrelor monotherapy was associated with significantly less BARC 2, 3, or 5 bleeding among prior CABG patients compared with DAPT (4.9% vs 9.6%, hazard ratio [HR] 0.50, 95% confidence interval [CI]: 0.28 to 0.90; pinteraction=0.676) and similar rates of death, MI or stroke (10.0% vs 8.7%, HR 1.14, 95% CI: 0.70 to 1.87; pinteraction=0.484). When comparing target vessel type, treatment effects were consistent among graft- and native-vessel interventions. CONCLUSIONS: In high-risk patients with prior CABG, ticagrelor monotherapy reduced bleeding without compromising ischaemic outcomes compared with ticagrelor plus aspirin.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

EuroIntervention

DOI

EISSN

1969-6213

Publication Date

December 2, 2022

Volume

18

Issue

11

Start / End Page

e897 / e909

Location

France

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Stroke
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Humans
  • Hemorrhage
  • Drug Therapy, Combination
  • Coronary Artery Bypass
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sardella, G., Beerkens, F. J., Dangas, G., Cao, D., Baber, U., Sartori, S., … Mehran, R. (2022). Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention, 18(11), e897–e909. https://doi.org/10.4244/EIJ-D-22-00319
Sardella, Gennaro, Frans J. Beerkens, George Dangas, Davide Cao, Usman Baber, Samantha Sartori, David J. Cohen, et al. “Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.EuroIntervention 18, no. 11 (December 2, 2022): e897–909. https://doi.org/10.4244/EIJ-D-22-00319.
Sardella G, Beerkens FJ, Dangas G, Cao D, Baber U, Sartori S, et al. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 2;18(11):e897–909.
Sardella, Gennaro, et al. “Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.EuroIntervention, vol. 18, no. 11, Dec. 2022, pp. e897–909. Pubmed, doi:10.4244/EIJ-D-22-00319.
Sardella G, Beerkens FJ, Dangas G, Cao D, Baber U, Sartori S, Cohen DJ, Briguori C, Gil R, Nicolas J, Zhang Z, Dudek D, Kunadian V, Kornowski R, Weisz G, Claessen B, Marx S, Escaned J, Huber K, Collier T, Moliterno DJ, Ohman EM, Krucoff MW, Kastrati A, Steg PG, Angiolillo DJ, Mehta S, Shlofmitz R, Sharma S, Pocock S, Gibson CM, Mehran R. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 2;18(11):e897–e909.

Published In

EuroIntervention

DOI

EISSN

1969-6213

Publication Date

December 2, 2022

Volume

18

Issue

11

Start / End Page

e897 / e909

Location

France

Related Subject Headings

  • Treatment Outcome
  • Ticagrelor
  • Stroke
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Humans
  • Hemorrhage
  • Drug Therapy, Combination
  • Coronary Artery Bypass